Bohner H, Zimmer T, Hopfenmuller W, Berger G, Buhr HJ: Detection and prognosis of recurrent gastric cancer–is routine follow-up after gastrectomy worthwhile? Hepatogastroenterology 2000, 47: 1489-1494.
CAS
PubMed
Google Scholar
Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997, 8: 163-168. 10.1023/A:1008243606668
Article
CAS
PubMed
Google Scholar
Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jager E: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008, 26: 1435-1442. 10.1200/JCO.2007.13.9378
Article
CAS
PubMed
Google Scholar
Gubanski M, Johnsson A, Fernebro E, Kadar L, Karlberg I, Flygare P, Berglund A, Glimelius B, Lind PA: Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer 2010, 13: 155-161. 10.1007/s10120-010-0553-4
Article
CAS
PubMed
Google Scholar
Kang JH, Lee SI, Lim d H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH: Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012, 30: 1513-1518. 10.1200/JCO.2011.39.4585
Article
CAS
PubMed
Google Scholar
Maugeri-Saccà M, Pizzuti L, Sergi D, Barba M, Belli F, Fattoruso SI, Giannarelli D, Amodio A, Boggia S, Vici P, Di Lauro L: Folfiri as second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. J Exp Clin Cancer Res 2013, 32: 67. 10.1186/1756-9966-32-67
Article
PubMed Central
PubMed
Google Scholar
Di Lauro L, Giacinti L, Grazia Arena M, Sergi D, Fattoruso SI, Giannarelli D, Lopez M: Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastastic gastric or gastroesophageal junction adenocarcinoma. J Exp Clin Cancer Res 2009, 28: 34. 10.1186/1756-9966-28-34
Article
PubMed Central
PubMed
Google Scholar
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376: 687-697. 10.1016/S0140-6736(10)61121-X
Article
CAS
PubMed
Google Scholar
Lim T, Lee J, Lee DJ, Lee HY, Han B, Baek KK, Ahn HK, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kim KM, Kang WK: Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother Pharmacol 2011, 68: 255-262. 10.1007/s00280-011-1653-5
Article
PubMed Central
CAS
PubMed
Google Scholar
Kim C, Lee JL, Choi YH, Kang BW, Ryu MH, Chang HM, Kim TW, Kang YK: Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs 2012, 30: 306-315. 10.1007/s10637-010-9531-2
Article
CAS
PubMed
Google Scholar
Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR: An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011, 47: 1511-1520. 10.1016/j.ejca.2011.04.006
Article
CAS
PubMed
Google Scholar
Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ, Kelsen DP: A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs 2011, 29: 1475-1481. 10.1007/s10637-010-9474-7
Article
CAS
PubMed
Google Scholar
Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP: Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011, 29: 868-874. 10.1200/JCO.2010.32.0770
Article
PubMed Central
CAS
PubMed
Google Scholar
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355: 11-20. 10.1056/NEJMoa055531
Article
CAS
PubMed
Google Scholar
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345: 725-730. 10.1056/NEJMoa010187
Article
CAS
PubMed
Google Scholar
Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, Yonemura Y, Ansaloni L: Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol 2014, 40: 12-26. 10.1016/j.ejso.2013.10.019
Article
CAS
PubMed
Google Scholar
Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Mizuno M, Miura M, Ikeda M, Ikeda S, Nakajima G, Yonemura J, Yuuba T, Masuda S, Kimura H, Matsuki N: Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol 2009, 100: 311-316. 10.1002/jso.21324
Article
CAS
PubMed
Google Scholar
Mok YJ, Koo BW, Whang CW, Kim SM, Maruyama K, Sasako M, Kinoshita T: Cancer of the stomach: a review of two hospitals in Korea and Japan. World J Surg 1993, 17: 777-782. 10.1007/BF01659094
Article
CAS
PubMed
Google Scholar
Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D: Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010, 17: 2370-2377. 10.1245/s10434-010-1039-7
Article
PubMed
Google Scholar
Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011, 18: 1575-1581. 10.1245/s10434-011-1631-5
Article
PubMed Central
PubMed
Google Scholar
Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ: Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 1993, 72: 2089-2097. 10.1002/1097-0142(19931001)72:7<2089::AID-CNCR2820720706>3.0.CO;2-H
Article
CAS
PubMed
Google Scholar
Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D: Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2009, 116: 5608-5618. 10.1002/cncr.25356
Article
Google Scholar
Glockzin G, von Breitenbuch P, Schlitt HJ, Piso P: Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: A matched-pair analysis. J Surg Oncol 2013, 107: 574-578. 10.1002/jso.23228
Article
CAS
PubMed
Google Scholar
Csoka K, Tholander B, Gerdin E, de la Torre M, Larsson R, Nygren P: In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1997, 72: 1008-1012. 10.1002/(SICI)1097-0215(19970917)72:6<1008::AID-IJC15>3.0.CO;2-0
Article
CAS
PubMed
Google Scholar
Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J, Nygaard R, Schmiegelow K, Larsson R, Lonnerholm G: Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 2003, 122: 376-385. 10.1046/j.1365-2141.2003.04442.x
Article
CAS
PubMed
Google Scholar
Lindhagen E, Nygren P, Larsson R: The fluorometric microculture cytotoxicity assay. Nat Protoc 2008, 3: 1364-1369. 10.1038/nprot.2008.114
Article
CAS
PubMed
Google Scholar
Piessen G, Messager M, Le Malicot K, Robb WB, Di Fiore F, Guilbert M, Moreau M, Cristophe V, Adenis A, Mariette C: Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADC10. BMC Cancer 2013, 13: 281. 10.1186/1471-2407-13-281
Article
PubMed Central
CAS
PubMed
Google Scholar
Hawkes E, Okines AF, Papamichael D, Rao S, Ashley S, Charalambous H, Koukouma A, Chau I, Cunningham D: Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. Eur J Cancer 2011, 47: 1146-1151. 10.1016/j.ejca.2010.12.021
Article
CAS
PubMed
Google Scholar
Nygren P, Fridborg H, Csoka K, Sundstrom C, de la Torre M, Kristensen J, Bergh J, Hagberg H, Glimelius B, Rastad J, et al.: Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 1994, 56: 715-720. 10.1002/ijc.2910560517
Article
CAS
PubMed
Google Scholar
Samalin E, Afchain P, Thezenas S, Abbas F, Romano O, Guimbaud R, Becouarn Y, Desseigne F, Edeline J, Mitry E, Bouche O, Adenis A, Aparicio T, Dorval E, Kramar A, Ychou M: Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. Clin Res Hepatol Gastroenterol 2011, 35: 48-54. 10.1016/j.gcb.2010.06.010
Article
CAS
PubMed
Google Scholar
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000, 343: 905-914. 10.1056/NEJM200009283431302
Article
CAS
PubMed
Google Scholar
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26: 2013-2019. 10.1200/JCO.2007.14.9930
Article
CAS
PubMed
Google Scholar
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28: 4697-4705. 10.1200/JCO.2009.27.4860
Article
CAS
PubMed
Google Scholar
Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012, 30: 2119-2127. 10.1200/JCO.2011.39.9824
Article
CAS
PubMed
Google Scholar
Fujimori Y, Inokuchi M, Takagi Y, Kato K, Kojima K, Sugihara K: Prognostic value of RKIP and p-ERK in gastric cancer. J Exp Clin Cancer Res 2012, 31: 30. 10.1186/1756-9966-31-30
Article
PubMed Central
CAS
PubMed
Google Scholar
Zhi K, Shen X, Zhang H, Bi J: Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancer. J Exp Clin Cancer Res 2010, 29: 66. 10.1186/1756-9966-29-66
Article
PubMed Central
PubMed
Google Scholar
Kubota T, Weisenthal L: Chemotherapy sensitivity and resistance testing: to be “standard” or to be individualized, that is the question. Gastric Cancer 2006, 9: 82-87. 10.1007/s10120-006-0366-7
Article
CAS
PubMed
Google Scholar
Kim JH, Lee KW, Kim YH, Lee KH, Oh do Y, Kim J, Yang SH, Im SA, Choi SH, Bang YJ: Individualized tumor response testing for prediction of response to Paclitaxel and Cisplatin chemotherapy in patients with advanced gastric cancer. J Korean Med Sci 2010, 25: 684-690. 10.3346/jkms.2010.25.5.684
Article
PubMed Central
CAS
PubMed
Google Scholar
Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004, 22: 3284-3292. 10.1200/JCO.2004.10.012
Article
CAS
PubMed
Google Scholar
Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dube P, Glehen O: Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010, 28: 63-68. 10.1200/JCO.2009.23.9285
Article
PubMed
Google Scholar
Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Ohashi N, Ito Y, Nakayama G, Koike M, Yamamura Y, Nakao A: In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. Int J Clin Oncol 2006, 11: 449-453. 10.1007/s10147-006-0618-x
Article
CAS
PubMed
Google Scholar